<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397185</url>
  </required_header>
  <id_info>
    <org_study_id>BCL IDE</org_study_id>
    <nct_id>NCT04397185</nct_id>
  </id_info>
  <brief_title>Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer</brief_title>
  <official_title>Randomized Prospective Trial of Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CairnSurgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CairnSurgical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicenter, 1:1 randomized, controlled trial is designed to evaluate the&#xD;
      safety and effectiveness of the Breast Cancer Locator (BCL) in subjects with non-palpable&#xD;
      invasive breast cancer or ductal carcinoma in situ (DCIS). Subjects will be randomized to&#xD;
      breast conserving surgery (BCS) utilizing either the BCL or wire localization (WL) to guide&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BCL System is intended to be used to guide a surgeon when performing partial mastectomy&#xD;
      for breast cancer and to minimize positive margins. The purpose of this study is to provide&#xD;
      evidence that the BCL is safe, effective, and non-inferior to the standard of care (WL) in&#xD;
      the removal of non-palpable invasive breast cancer and DCIS.&#xD;
&#xD;
      Investigators in the intervention group will be provided with a three dimensional (3D) image&#xD;
      of the cancer in the breast which allows them to visualize the closest distance from the&#xD;
      tumor to the skin and the chest wall and quantifies those distances. Investigators will also&#xD;
      use a BCL, which is a patient specific, plastic, bra-like form that is transiently placed on&#xD;
      the breast prior to surgery and allows the Investigator to mark the projected edges of the&#xD;
      tumor on the breast skin and to place bracketing wires inside the breast which define the&#xD;
      center of the cancer and distances 1 cm from the tumor edges defined by pre-operative supine&#xD;
      MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Pathologist will be blinded to the study assignment (BCL vs. WL)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Positive margin rate</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To provide evidence that the positive margin rate following BCS using the BCL is not inferior to the standard of care (WL) for surgical guidance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specimen volumes</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare specimen volumes for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-excision rate</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare re-excision rate for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer localization rate</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare cancer localization rate for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative times</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare operative times for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare adverse event rate for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of additional shave biopsies</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare rate of additional shave biopsies for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of care</measure>
    <time_frame>At completion of study recruitment, approximately 18 months after first subject enrolled</time_frame>
    <description>To compare costs of care for women randomized to BCL vs. WL-guided BCS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Locator (BCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject randomized to BCL surgical guidance to perform partial mastectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wire Localization (WL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject randomized to WL surgical guidance to perform partial mastectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breast Cancer Locator (BCL) guided partial mastectomy</intervention_name>
    <description>The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.</description>
    <arm_group_label>Breast Cancer Locator (BCL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wire Localized (WL) partial mastectomy</intervention_name>
    <description>Standard of care procedure</description>
    <arm_group_label>Wire Localization (WL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Histologic diagnosis of invasive breast cancer or DCIS&#xD;
&#xD;
          -  The tumor cannot be definitively detected by palpation&#xD;
&#xD;
          -  The tumor is unifocal; possible satellite lesions &lt; 2 cm from primary are eligible&#xD;
&#xD;
          -  The tumor enhances on prone breast MRI imaging&#xD;
&#xD;
          -  The tumor is visible on mammography&#xD;
&#xD;
          -  The tumor is â‰¥ 1 cm in diameter on mammography or prone MRI&#xD;
&#xD;
          -  Subject and surgeon agree to perform BCS&#xD;
&#xD;
          -  Ability to voluntarily provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absolute contraindication to MRI, including presence of implanted electrical device&#xD;
             (e.g., pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or&#xD;
             near eyes&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
&#xD;
          -  Contraindication to use of gadolinium-based intravenous contrast, including life-&#xD;
             threatening allergy&#xD;
&#xD;
          -  Compromised renal function including chronic, severe kidney disease (GFR &lt; 30&#xD;
             ml/min/1.73m2), or acute kidney injury&#xD;
&#xD;
          -  Pregnancy - In women of childbearing age a urine pregnancy test will be performed&#xD;
&#xD;
          -  Subjects who have received or plan to receive neoadjuvant chemotherapy&#xD;
&#xD;
          -  Sternal notch to nipple distance of &gt; 32 cm as measured in a sitting or standing&#xD;
             position&#xD;
&#xD;
          -  Measurement of widest circumference around breasts and arms &gt; 135 cm&#xD;
&#xD;
          -  Subjects with known allergy to materials present in the device&#xD;
&#xD;
          -  Use of localization with devices other than a localization wire, including&#xD;
             intraoperative ultrasound guidance, radiofrequency emitting implants, magnetic seeds,&#xD;
             radioactive seeds, and tissue inspection devices (MarginProbe)&#xD;
&#xD;
          -  Subject would require &gt; 2 localization wires, if randomized to standard of care&#xD;
&#xD;
          -  Multicentric tumors (additional tumors &gt; 2 cm from primary)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Gass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women &amp; Infants Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gisella Lopez</last_name>
    <phone>9788283752</phone>
    <email>lopez@cairnsurgical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Danielsen</last_name>
    <phone>508-736-0283</phone>
    <email>danielsen@cairnsurgical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Poonam Neki</last_name>
    </contact>
    <investigator>
      <last_name>Beth-Ann Lesnikoski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Boornazian</last_name>
    </contact>
    <investigator>
      <last_name>Nazanin Khakpour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mass General/North Shore Center for Outpatient Care</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Calistro</last_name>
    </contact>
    <investigator>
      <last_name>Suzanne Coopey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheshire Medical Center</name>
      <address>
        <city>Keene</city>
        <state>New Hampshire</state>
        <zip>03431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Lynch</last_name>
    </contact>
    <investigator>
      <last_name>H.E. Guy Burman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Rosenkranz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kari Rosenkranz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Ryan</last_name>
    </contact>
    <investigator>
      <last_name>Jessica Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey Abbis</last_name>
    </contact>
    <investigator>
      <last_name>Stacey Abbis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Peter's Hospital</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Pesek</last_name>
    </contact>
    <investigator>
      <last_name>Sarah Pesek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings County Hospital Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debora Chrispin</last_name>
      <email>chrispid@nychhc.org</email>
    </contact>
    <investigator>
      <last_name>Jaime Alberty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Edmonson</last_name>
    </contact>
    <investigator>
      <last_name>David Edmonson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Gass, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kent Hospital</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joni Harris</last_name>
      <email>JonHarris@kentri.org</email>
    </contact>
    <investigator>
      <last_name>Jamie Patterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Hunt</last_name>
    </contact>
    <investigator>
      <last_name>Kelly Hunt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwestern Vermont Medical Center</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Cullinane</last_name>
    </contact>
    <investigator>
      <last_name>Gina Lamb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutland Regional Medical Center</name>
      <address>
        <city>Rutland</city>
        <state>Vermont</state>
        <zip>05701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tonya Welch</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Conway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

